Abstract |
This study describes a potential effect of topical gentian violet on cutaneous infection and nasal carriage with methicillin-resistant Staphylococcus aureus (MRSA). 0.5% gentian violet was used in 28 cases of skin lesions once a day, while a 0.3% solution was applied on the nasal vestibules of nine cases twice a day. The period for eradication in the 28 skin cases was 9.1 +/- 6.0 days. It was 15.3 +/- 9.0 days for the nine nasal lesions. The minimal inhibitory concentration (MIC) of gentian violet against MRSA from the four isolated strains was 0.0225 +/- 0.0096 microg/mL. No adverse reactions occurred throughout the study. It is suggested that gentian violet may be potentially effective against MRSA.
|
Authors | M Okano, S Noguchi, K Tabata, Y Matsumoto |
Journal | International journal of dermatology
(Int J Dermatol)
Vol. 39
Issue 12
Pg. 942-4
(Dec 2000)
ISSN: 0011-9059 [Print] England |
PMID | 11168669
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Anti-Infective Agents, Local
- Gentian Violet
- Methicillin
|
Topics |
- Administration, Topical
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anti-Infective Agents, Local
(administration & dosage, therapeutic use)
- Child
- Child, Preschool
- Female
- Gentian Violet
(administration & dosage, therapeutic use)
- Humans
- Infant
- Male
- Methicillin
(pharmacology)
- Methicillin Resistance
- Microbial Sensitivity Tests
- Middle Aged
- Nasal Cavity
(microbiology)
- Prospective Studies
- Staphylococcal Skin Infections
(drug therapy, microbiology)
- Staphylococcus aureus
(drug effects, isolation & purification)
|